Inactive Research Support

Funding Opportunities

Title Description Expires Grant Number
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to publicize a competition for Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRCs). These Centers promote collaborative basic, translational, and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. The Centers also provide outstanding environments for the training of new researchers capable of addressing high priority research objectives in the muscular dystrophies. Center investigators are expected to participate in important community outreach efforts to increase awareness of their research activities in the patient and advocacy communities and to incorporate community perspectives into the conduct of patient-centered research.

RFA-AR-21-008
2020 Request for Applications (RFA): International Research Grants in Congenital Muscular Dystrophy

Purpose: Promote the discovery of underlying disease mechanisms and the preclinical development of potential therapies, as well as the clinical translation of those efforts. As cardiac issues are the most hunting fear for patients and families we are particularly interested in receiving applications focused on testing potential therapies for LMNA-related cardiac pathologies.

Areas of Interest: Including but not limited to, 1) unraveling pathways involved in skeletal muscle or cardiac muscle pathology, 2) identifying novel drug targets or gene therapies, and 3) testing new strategies to treat disease or any of its incapacitating consequences (e.g. contractures, respiratory function decline, etc).

Up to $50,000 funding for Two years

We will also accept applications proposing to create or improve disease models (e.g. animal models, patient-derived cell models), and encourage applications on biomarker discovery or functional outcome measures to assess therapeutic impact in an effort to bring LMNA-CMD closer to Clinical Trial Readiness.

2020 Request for Applications (RFA): International Research Grants in Congenital Muscular Dystrophy: SELENON

Purpose: Promote the discovery of underlying disease mechanisms and preclinical development of potential therapies, as well as the clinical translation of those efforts.

Areas of Interest: Including but not limited to, 1) understanding the cause of disease, 2) unraveling pathways involved in disease, 3) identifying novel drug targets or gene therapies, and 4) testing new strategies to treat disease or any of its incapacitating consequences (e.g. contractures, respiratory function decline).

We will also accept applications proposing to create or improve disease models (e.g. animal models, patient-derived cell models), and encourage applications on biomarker discovery or functional outcome measures to assess therapeutic impact in an effort to bring SELENON-RM closer to Clinical Trial Readiness.

2020 Request for Applications (RFA): International Research Grants in Congenital Muscular Dystrophy: αDG

Purpose: Promote the discovery of underlying disease mechanisms and preclinical development of potential therapies, as well as the clinical translation of those efforts. In addition to the symptoms of muscle weakness, most forms of congenital α-dystroglycanopathy involve brain development defects which may express as cognitive impairment, seizures, or visual impairment. For affected individuals and their families, the search for solutions to manage the cognitive and neural complications of αDG is as important, if not more so than muscle weakness. For this reason, we strongly encourage proposals addressing cognitive and neural complications. For example, establishing 3D mini-brains to study the developmental defects and potential treatments.

Areas of Interest: Including but not limited to, 1) understanding the cause of disease, 2) unraveling pathways involved in disease, 3) identifying novel drug targets or gene therapies, and 4) testing new strategies to treat disease or any of its incapacitating consequences (e.g. cognitive impairment, seizures, vision, contractures, respiratory function decline).

We will also accept applications proposing to create or improve disease models (e.g. animal models, patient-derived cell models), and encourage applications on biomarker discovery or functional outcome measures to assess therapeutic impact in an effort to bring αDG closer to Clinical Trial Readiness.

Up to 50,000 for two years

αDG
2020 Request for Applications (RFA): International Research Grants in Congenital Muscular Dystrophy: Collagen VI

Purpose: Promote the discovery of underlying disease mechanisms and the preclinical development of potential therapies, as well as the clinical translation of those efforts.

Areas of Interest: Including but not limited to, 1) understanding the cause of disease, 2) understanding tissue-specific phenotypes, 3) unraveling pathways involved in disease, 4) identifying novel drug targets or gene therapies, and 5) testing new strategies to treat disease or any of its incapacitating consequences (e.g. contractures, respiratory function decline).

Up to $50,000 for Two years

We will also accept applications proposing to create or improve disease models (e.g. animal models, patient-derived cell models), and encourage applications on biomarker discovery or functional outcome measures to assess therapeutic impact in an effort to bring COL6-CMD closer to Clinical Trial Readiness.

2020 Request for Applications (RFA): International Research Grants in Congenital Muscular Dystrophy: LAMA2

Purpose: Promote the discovery of underlying disease mechanisms and preclinical development of potential therapies, as well as the clinical translation of those efforts.

Areas of Interest: Including but not limited to, 1) understanding the cause of disease, 2) unraveling pathways involved in disease, 3) identifying novel drug targets or gene therapies, and 4) testing new strategies to treat disease or any of its detrimental consequences (e.g. fibrosis, seizures, contractures, respiratory function decline).

We also encourage applications on biomarker discovery or functional outcome measures to assess therapeutic impact in an effort to bring LAMA2-CMD closer to Clinical Trial Readiness.

Field Initiated Projects Program (Research)

The purpose of the Field Initiated (FI) Projects program is to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities. Another purpose of the FI Projects program is to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended (Act).

In carrying out a research activity under a FI Projects research grant, a grantee must identify one or more hypotheses or research questions and, based on the hypotheses or research questions identified, perform an intensive, systematic study directed toward producing (1) new scientific knowledge or (2) better understanding of the subject, problem studied, or body of knowledge.

$200,000/yr for 36months

HHS-2020-ACL-NIDILRR-IFRE-0373
Field Initiated Projects Program (Development)

The purpose of the Field Initiated (FI) Projects program is to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities. Another purpose of the FI Projects program is to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended (Act).

In carrying out a development activity under a FI Projects development grant, a grantee must use knowledge and understanding gained from research to create materials, devices, systems, methods, measures, techniques, tools, prototypes, processes, or intervention protocols that are beneficial to the target population.

$200,000/yr for 36 months

HHS-2020-ACL-NIDILRR-IFDV-0374
Advanced Rehabilitation Research Training (ARRT) Program - Health and Function Department of Health and Human Services Administration for Community Living

The purpose of NIDILRR’s ARRT program, which is funded through the Disability and Rehabilitation Research Projects and Centers Program, is to provide advanced research training and experience to individuals with doctorates, or similar advanced degrees, who have clinical or other relevant experience. ARRT projects train rehabilitation researchers, including researchers with disabilities, with particular attention to research areas that support the implementation and objectives of the Rehabilitation Act, and that improve the effectiveness of services authorized under the Rehabilitation Act. ARRT projects must provide advanced research training to eligible individuals to enhance their capacity to conduct high-quality multidisciplinary disability and rehabilitation research to improve outcomes for individuals with disabilities in NIDILRR’s major domain of health and function.

$200,000 per year (60 months)

HHS-2020-ACL-NIDILRR-ARHF-0369
Advanced Rehabilitation Research Training (ARRT) Program - Community Living and Participation Department of Health and Human Services Administration for Community Living

The purpose of NIDILRR’s ARRT program, which is funded through the Disability and Rehabilitation Research Projects and Centers Program, is to provide advanced research training and experience to individuals with doctorates, or similar advanced degrees, who have clinical or other relevant experience. ARRT projects train rehabilitation researchers, including researchers with disabilities, with particular attention to research areas that support the implementation and objectives of the Rehabilitation Act, and that improve the effectiveness of services authorized under the Rehabilitation Act. ARRT projects under this opportunity announcement must provide advanced research training to eligible individuals to enhance their capacity to conduct high-quality multidisciplinary disability and rehabilitation research to improve outcomes for individuals with disabilities in NIDILRR’s major domain of community living and participation.

$200,000 per year (60 months)

HHS-2020-ACL-NIDILRR-ARCP-0368
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to publicize a competition for Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRCs). These Centers promote collaborative basic, translational and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. The Centers also provide outstanding environments for the training of new researchers capable of addressing high priority research objectives in the muscular dystrophies. Center investigators are expected to participate in important community outreach efforts to increase awareness of their research activities in the patient and advocacy communities and to incorporate community perspectives into the conduct of patient-centered research.

RFA-NS-19-031
Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01)

The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients.  This is the Forms change reissue of PAR 16-020 and has replace PAR 16-020

PAR-18-534
Disability and Rehabilitation Research Projects (DRRP) Program: Health and Function (Research)

This particular DRRP opportunity is for an investigator-initiated project.  Applicants must decide whether to submit their proposed work as a research proposal or a development proposal.  The definitions of research and development are provided in each funding opportunity announcement (FOA). Here is how we describe research and development projects in the FOAs:

Research: A grantee must identify one or more hypotheses or research questions and, based on the hypotheses or research questions identified, perform an intensive, systematic study directed toward producing (1) new or full scientific knowledge or (2) understanding of the subject or problem studied.

Development: A grantee must use knowledge and understanding gained from research to create models, methods, tools, applications, and devices beneficial to the target population, including design and development of prototypes and processes. 

HHS-2018-ACL-NIDILRR-DPHF-0268
Disability and Rehabilitation Research Projects (DRRP) Program: Health and Function (Development)

This particular DRRP opportunity is for an investigator-initiated project.  Applicants must decide whether to submit their proposed work as a research proposal or a development proposal.  The definitions of research and development are provided in each funding opportunity announcement (FOA). Here is how we describe research and development projects in the FOAs:

Research: A grantee must identify one or more hypotheses or research questions and, based on the hypotheses or research questions identified, perform an intensive, systematic study directed toward producing (1) new or full scientific knowledge or (2) understanding of the subject or problem studied.

Development: A grantee must use knowledge and understanding gained from research to create models, methods, tools, applications, and devices beneficial to the target population, including design and development of prototypes and processes. 

HHS-2018-ACL-NIDILRR-DPHF-0269
Advanced Rehabilitation Research Training (ARRT) grant

HHS-2018-ACL-NIDILRR-ARCP-0240
Advanced Rehabilitation Research Training (ARRT) Program - Community Living and Participation
Department of Health and Human Services
Administration for Community Living

HHS-2018-ACL-NIDILRR-ARCP-0240
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50)

The purpose of this Funding Opportunity Announcement (FOA) is to publicize a competition for Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRCs). These Centers promote collaborative basic, translational and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. The Centers also provide an outstanding environment for the training of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Center investigators are expected to participate in important community outreach efforts to increase awareness and convey the importance and implications of their research activities to the patient and advocacy communities.

RFA-AR-18-001

Information for Researchers

Funding Opportunities for Muscular Dystrophy Research

FY20 Duchenne Muscular Dystrophy Research Program (DMDRP)

Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers

CureDuchenne Ventures 2020 Pitch Contest Submission Deadline: July 13, 2020!

Muscular Dystrophy Research Support from MDCC Member Organizations

2018 Supported Projects
2017 Supported Projects
2016 Supported Projects
2015 Supported Projects
Was this page helpful?
Form Approved OMB# 0925-0648 Exp. Date 05/31/2021